Novo Nordisk is switching up a gear its efforts to acquire Belgian biopharma Ablynx, with a heightened offer valued at around 2.6 billion euros. More: Novo makes second move on Ablynx Source: News
read moreUS regulators have accepted for review Cambridge, UK-based Acacia Pharma’s application for post-operative nausea and vomiting (PONV) drug Baremsis. More: Acacia’s PONV drug under US review Source: News
read moreIt’s been just a year and a half since Pernix Therapeutics cut 23% of its sales force, but the company is downsizing once again. More: Pernix lays off another 41 sales staffers as Treximet generics loom Source: fierce
read moreWith all the commotion and fury from different directions targeting Sanofi’s Dengvaxia, the Philippines has now only suspended the vaccine’s approval and fined the drugmaker a symbolic $2,000. More: Philippines suspends Dengvaxia approval, fines Sanofi a symbolic ,000 Source: fierce
read moreTrailing in the wake of Pfizer’s Ibrance, Novartis’ Kisqali is one step closer to nabbing a regulatory boost. The FDA has granted the breast cancer fighter its breakthrough designation as a first-line treatment for premenopausal women with HR-positive, HER2-negative breast
read moreWith the New Year comes a new tax system in the U.S., and now many analysts and consultants are digging into how the GOP’s reform will affect major pharma players. This week, Leerink Partners analysts are out with their picks
read more© 1994 - 2026 B.M. Pharmaceuticals